Danchenko N[au] - Search Results

Year	Number of Results
1971	1
1975	1
2004	2
2006	1
2007	1
2008	4
2009	4
2010	2
2011	1
2012	5
2013	2
2014	2
2015	1
2016	3
2017	5
2018	1
2019	1
2020	4
2021	2
2022	2

1

Challenges in measuring and valuing productivity costs, and their relevance in mood disorders.

Lensberg BR, Drummond MF, Danchenko N, Despiégel N, François C. Lensberg BR, et al. Among authors: danchenko n. Clinicoecon Outcomes Res. 2013 Nov 18;5:565-73. doi: 10.2147/CEOR.S44866. eCollection 2013. Clinicoecon Outcomes Res. 2013. PMID: 24273412 Free PMC article. Review.

2

Development of a family functioning scale for major depressive disorder.

DiBenedetti DB, Danchenko N, François C, Lewis S, Davis KH, Fehnel SE. DiBenedetti DB, et al. Among authors: danchenko n. Curr Med Res Opin. 2012 Mar;28(3):303-13. doi: 10.1185/03007995.2012.658910. Epub 2012 Feb 9. Curr Med Res Opin. 2012. PMID: 22256800 Review.

3

The use and performance of productivity scales to evaluate presenteeism in mood disorders.

Despiégel N, Danchenko N, François C, Lensberg B, Drummond MF. Despiégel N, et al. Among authors: danchenko n. Value Health. 2012 Dec;15(8):1148-61. doi: 10.1016/j.jval.2012.08.2206. Value Health. 2012. PMID: 23244819 Free article. Review.

4

Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant.

Atsou K, Ereshefsky L, Brignone M, Danchenko N, Diamand F, Mucha L, Touya M, Becker R, François C. Atsou K, et al. Among authors: danchenko n. Expert Rev Pharmacoecon Outcomes Res. 2021 Feb;21(1):29-42. doi: 10.1080/14737167.2021.1855979. Epub 2021 Jan 17. Expert Rev Pharmacoecon Outcomes Res. 2021. PMID: 33307885

5

Comparative efficacy, safety, and cost-effectiveness of abobotulinumtoxinA and onabotulinumtoxinA in children with upper limb spasticity: a systematic literature review, indirect treatment comparison, and economic evaluation.

Danchenko N, Johnston KM, Haeussler K, Whalen J. Danchenko N, et al. J Med Econ. 2021 Jan-Dec;24(1):949-961. doi: 10.1080/13696998.2021.1957582. J Med Econ. 2021. PMID: 34340647 Free article.

6

Patient-centered assessment of cognitive symptoms of depression.

Fehnel SE, Forsyth BH, DiBenedetti DB, Danchenko N, François C, Brevig T. Fehnel SE, et al. Among authors: danchenko n. CNS Spectr. 2016 Feb;21(1):43-52. doi: 10.1017/S1092852913000643. Epub 2013 Sep 25. CNS Spectr. 2016. PMID: 24067243

7

The effect of vortioxetine on overall patient functioning in patients with major depressive disorder.

Florea I, Loft H, Danchenko N, Rive B, Brignone M, Merikle E, Jacobsen PL, Sheehan DV. Florea I, et al. Among authors: danchenko n. Brain Behav. 2017 Feb 2;7(3):e00622. doi: 10.1002/brb3.622. eCollection 2017 Mar. Brain Behav. 2017. PMID: 28293465 Free PMC article.

8

Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden.

Danchenko N, Satia JA, Anthony MS. Danchenko N, et al. Lupus. 2006;15(5):308-18. doi: 10.1191/0961203306lu2305xx. Lupus. 2006. PMID: 16761508 Review.

9

New advances in measurement of complement activation: lessons of systemic lupus erythematosus.

Liu CC, Manzi S, Danchenko N, Ahearn JM. Liu CC, et al. Among authors: danchenko n. Curr Rheumatol Rep. 2004 Oct;6(5):375-81. doi: 10.1007/s11926-004-0012-5. Curr Rheumatol Rep. 2004. PMID: 15355750 Review.

10

Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia.

Misra VP, Danchenko N, Maisonobe P, Lundkvist J, Hunger M. Misra VP, et al. Among authors: danchenko n. J Clin Mov Disord. 2020 Feb 11;7:2. doi: 10.1186/s40734-020-0083-0. eCollection 2020. J Clin Mov Disord. 2020. PMID: 32071728 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results